Skip to main content
. 2021 May 23;12(3):1166–1178. doi: 10.1016/j.jcmgh.2021.05.011

Figure 2.

Figure 2

Trametinib increases surface expression of MHC-I on iCCA tumor cell lines. Median fluorescence intensity (MFI) of surface (A) MHC-I and (B) PD-L1 expression of SB1 cells treated with 25 nmol/L trametinib for 24 hours measured by flow cytometry (n = 7 per group). (C) Representative histogram plots of surface MHC-I (left section) and PD-L1 (right section) expression on SB1 cells after 25 nmol/L trametinib (red) treatment vs control (blue) for 24 hours. MFI of surface (D) MHC-I and (E) PD-L1 expression of LD-1 cells treated with 25 nmol/L trametinib for 24 hours measured by flow cytometry (n = 7 per group). (F) Representative histogram plots of surface MHC-I (left section) and PD-L1 (right section) expression on LD-1 cells after 25 nmol/L trametinib (red) treatment vs control (blue) for 24 hours. MFI of surface (G) MHC-I and (H) PDL-1 expression of EGI-1 cells treated with 25 nmol/L trametinib for 24 hours measured by flow cytometry (n = 7 per group). (F) Representative histogram plots of surface MHC-I (left section) and PD-L1 (right section) expression on EGI-1 cells after 25 nmol/L trametinib (red) treatment vs control (blue) for 24 hours. Data represent means ± SD. ∗P < .05, and ∗∗∗∗P < .0001; Student t test.